Valneva SE, a specialty vaccine company, received a termination notice from the UK Government (HMG) in relation to the Supply Agreement for its COVID-19 vaccine candidate, VLA2001. The contract provides HMG with the right to terminate. HMG has alleged that the Company is in breach of its obligations under the Supply Agreement, but the Company strenuously denies this.   Valneva is continuing its VLA2001 development plan. Its pivotal Phase 3 trial, Cov-Compare, is ongoing at Public Health Englan...